Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poliovirus type 1 antigen (formaldehyde inactivated)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Poliovirus type 1 antigen (formaldehyde inactivated) is a purified and formaldehyde-inactivated suspension of the Mahoney strain of poliovirus Type 1. It is used as part of the trivalent or monovalent Inactivated Poliovirus Vaccine (IPV) for active immunization against paralytic disease caused by wild-type and vaccine-derived strains of Poliovirus Type 1. The mechanism of action involves induction of neutralizing antibodies that confer protective immunity against infection with live virus. The primary indication is prevention of poliomyelitis, and it is administered to infants, children, and adults as part of routine immunization schedules[2][4][7]. The product has been developed using continuous lines or primary cultures from monkey kidney cells[7].
- Brand names
- IPOLKinrixPediarixPentacelQuadracelVaxelisIMOVAX Polio
- Other names
- poliovirus vaccine inactivated, type 1 (Mahoney)inactivated poliomyelitis vaccine (V.C.O.) type 1 Mahoney
Beyond the preview
Go deeper on poliovirus type 1 antigen (formaldehyde inactivated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poliovirus type 1 antigen (formaldehyde inactivated).